Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

TNFRSF1A, TRAPS and multiple sclerosis

Nature Reviews Neurology volume 5, pages 528–529 (2009)Cite this article

A genome-wide association study has identified the R92Q variant of the TNFRSF1A gene as a new susceptibility locus for multiple sclerosis. This locus is of special interest because the R92Q substitution was previously detected in a group of multiple sclerosis patients who had additional symptoms compatible with the autoinflammatory syndrome TRAPS.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 7, 516–526 (2008).

    Article  Google Scholar 

  2. De Jager, P. L. et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41, 776–782 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Baranzini, S. E. et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum. Mol. Genet. 18, 2078–2090 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gold, R., Linington, C. & Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953–1971 (2006).

    Article  PubMed  Google Scholar 

  5. Spuler, S. et al. Multiple sclerosis: prospective analysis of TNF-α and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J. Neuroimmunol. 66, 57–64 (1996).

    Article  CAS  PubMed  Google Scholar 

  6. [No authors listed] TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 444–445 (1999).

  7. Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621–668 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kümpfel, T. et al. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum. 56, 2774–2783 (2007).

    Article  PubMed  Google Scholar 

  9. Kümpfel, T. et al. Multiple sclerosis and the TNFRSF1A R92Q-mutation: clinical characteristics of 21 cases. Neurology 71, 1812–1820 (2008).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

R. Hohlfeld is supported by the German Research Foundation (grant number SFB 571, A1).

Author information

Author notes

  1. T. Kümpfel, Institute of Clinical Neuroimmunology—Campus Grosshadern, University of Munich, Marchioninistrasse 15, D-81377 Munich, Germany tania.kuempfel@med.uni-muenchen.de

Authors and Affiliations

  1. Institute of Clinical Neuroimmunology—Campus Grosshadern, Ludwig Maximilians University of Munich, Germany

    Tania Kümpfel & Reinhard Hohlfeld

Authors
  1. Tania Kümpfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reinhard Hohlfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

T. Kümpfel has acted as a consultant for and received grants from Bayer Schering Pharma, Biogen-Idec, Merck-Serono and Teva. R. Hohlfeld has acted as a consultant for and received grants from Bayer Schering Pharma, Biogen-Idec Merck-Serono, Novartis and Teva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kümpfel, T., Hohlfeld, R. TNFRSF1A, TRAPS and multiple sclerosis. Nat Rev Neurol 5, 528–529 (2009). https://doi.org/10.1038/nrneurol.2009.154

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.154

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing